[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Spyre Therapeutics, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":99},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100651815","phase-2-a-study-of-spy072-in-adults-with-moderate-to-severe-hidradenitis-suppurativa-the-skylight-trial-100651815",false,"NCT07766005","A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)","A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-concept Trial to Assess the Efficacy and Safety of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa Receiving Standard of Care Treatment","Inclusion Criteria:\n\n* Clinical diagnosis of Hidradenitis Suppurativa with symptoms for at least 6 months before screening.\n* Hidradenitis suppurativa lesions in at least 2 distinct anatomical areas, with at least 1 area meeting Hurley Stage II or III criteria at screening and Day 1.\n* Total abscess and\u002For inflammatory nodule count of at least 5 at screening and Day 1.\n* Documented inadequate response, intolerance, or contraindication to at least 1 systemic therapy for hidradenitis suppurativa.\n\nExclusion Criteria:\n\n* More than 20 draining tunnels at screening or Day 1.\n* Hidradenitis suppurativa lesion expected to require incision and drainage within 4 weeks before Day 1, or major hidradenitis suppurativa surgery within 12 weeks before Day 1.\n* Another inflammatory or skin condition that could interfere with assessment of hidradenitis suppurativa.","ALL","18 Years","75 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This Phase 2 study will test whether the investigational medicine, SPY072, improves hidradenitis suppurativa (HS) in adults with moderate to severe disease receiving advanced standard of care treatment. About 150 participants will be assigned by chance to receive either SPY072 or placebo for 16 weeks. Participants will be followed after the treatment period to evaluate safety and how long treatment effects may last.",[27],"Hidradenitis Suppurativa (HS)",[29,30,31,32,33],"Hidradenitis suppurativa","Hidradenitis","Skin diseases","Sweat gland diseases","Skin and connective tissue diseases","NOT_YET_RECRUITING","2026-08-10",{"date":37,"type":38},"2026-08-14","ACTUAL",{"date":40,"type":21},"2026-09",{"date":42,"type":21},"2028-06",{"name":44,"class":45},"Spyre Therapeutics, Inc.","INDUSTRY",12,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":73},"100593896","phase-2-a-study-of-long-acting-antibodies-alone-and-in-combinations-for-moderate-to-severe-ulcerative-colitis-100593896","NCT07012395","A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis","Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative Colitis","SKYLINE-UC","Inclusion Criteria:\n\n* Diagnosis of UC for ≥3 months before Day 1, confirmed by endoscopy and histology either previously or during Screening\n* Active UC with disease extent of ≥15 cm from the anal verge, as confirmed by Screening endoscopy (up to approximately 15% allowed to have only proctitis)\n* Moderately to severely active disease as defined by a modified Mayo score of 5-9, rectal bleeding subscore of ≥1, and Mayo endoscopic subscore ≥2\n\nExclusion Criteria:\n\n* Current diagnosis of Crohn's disease or Inflammatory Bowel Disease (IBD)-Undefined\n* Confirmed or suspected fulminant colitis, toxic megacolon, bowel perforation and\u002For other conditions that will likely require surgery during induction\n* Failed 4 or more approved or investigational advanced therapy classes",{"count":56,"type":21},645,[24],"This is a Phase 2, multicenter, proof-of-concept platform study in adult participants with moderately to severely active ulcerative colitis (UC). The primary goal of the study is to assess the efficacy and safety of multiple interventions following intravenous (IV) induction and subcutaneous (SC) maintenance treatment.",[60,61,62,63],"Ulcerative Colitis","Inflammatory Bowel Diseases","Colitis","Colitis, Ulcerative","RECRUITING","2026-07-24",{"date":67,"type":38},"2026-07-28",{"date":69,"type":38},"2025-05-27",{"date":71,"type":21},"2028-03",{"name":44,"class":45},259,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":16,"minAge":17,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},"100563892","phase-1-a-study-of-spy002-072-in-healthy-volunteers-100563892","NCT06622070","A Study of SPY002-072 in Healthy Volunteers","A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of SPY002-072 in Healthy Participants","Inclusion Criteria:\n\n* Healthy men and women\n* Willing and able to attend the necessary visits to the CRU, comply with all testing requirements, remain at the study site unit for the duration of the confinement period and return for the outpatient visits\n\nExclusion Criteria:\n\n* Participation in more than one cohort\n* Evidence of clinically significant abnormality or disease\n* Known history of illicit drug use or drug abuse, cannabis\u002Fcannabinoid use, harmful alcohol use (at the Investigator's discretion), alcoholism, and\u002For smoking or nicotine-containing product use within 3 months prior to the first dose of study agent\n* History of severe allergic reactions or hypersensitivity\n* Donation or loss of ≥ 1 unit of whole blood within 1 month prior to dosing",true,"60 Years",{"count":84,"type":21},56,[86],"PHASE1","This is a Phase 1, randomized, double-blind, placebo-controlled, single-dose, first in human safety, tolerability, and pharmacokinetic study of SPY002-072 in healthy participants.",[89],"Healthy","2024-11-25",{"date":92,"type":38},"2024-11-27",{"date":94,"type":38},"2024-11-18",{"date":96,"type":21},"2026-08-08",{"name":44,"class":45},2,""]